This phenomenon could be attributed to the milder severity of the disease in DM patients (diabetes duration only >1 year and metformin as the only antidiabetic pharmacological treatment), as well as the high FFA and low insulin state during SGLT2i treatment, which increased CD36 degradation and thus decreased myocardial FFA uptake capacity (95, 96). This evidence concerns the gene CD36 and diabetes mellitus.